Norwegian company Vaccibody has through a new share issue completed a NOK 35 million financing.
The financing comes from both existing and new investors. The largest new investor is represented by Datum and partners, which will take a seat in the Board of Directors. Arctic Securities is the manager for the share issue.
According to Vaccibody, the share issue was significantly oversubscribed.
“We are very pleased to see such a great interest in Vaccibody AS and I look forward to take the company into a new stage by initiating our first clinical study. I very much welcome our new strong investor group and look forward to a fruitful collaboration in the years to come,” says CEO, Ole Henrik Brekke, in a statement.
The finalization will take place in the extraordinary general meeting on July 9th.
Vaccibody is a vaccine company based on the technology from the University of Oslo and Oslo University Hospital in the laboratories of Professors Bjarne Bogen and Inger Sandlie. The company develops technology for novel vaccines and an immunotherapy against HPV-induced malignancies.